Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468645 | 0.90 | OPRD1 (0.60) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1603346 | 0.90 | OPRD1 (0.61) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL12708343 | 0.89 | OPRD1 (0.72) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1602291 | 0.86 | OPRD1 (0.64) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1604037 | 0.86 | OPRD1 (0.62) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1603178 | 0.84 | OPRD1 (0.61) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL6191622 | 0.84 | OPRD1 (0.79) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1603518 | 0.83 | OPRD1 (0.59) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL5440034 | 0.83 | OPRD1 (0.65) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL1603427 | 0.82 | OPRD1 (0.72) | OPRD1KCNH2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | claimed |
| US-20070099957-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRA ZENECA AB (SE) | 2007-05-03 | — | — | US | claimed |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20070099957-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRA ZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099957-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRA ZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099957-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRA ZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099957-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | OPRM1, OPRD1, QDPR | OPRD1 2/4885KCNH2 72/4885OPRM1 1/4885 |
| US-20110082173-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | OPRM1, OPRD1, QDPR | OPRD1 2/4885KCNH2 72/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.